Literature DB >> 8396093

Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women.

M A Waugh1.   

Abstract

An open, non-comparative study was undertaken to assess the safety and efficacy of a single 1 g oral dose of azithromycin in patients with uncomplicated gonorrhoea. One hundred and eighteen patients (105 male, 13 female) took part in the study. Only patients culture-positive for Neisseria gonorrhoeae were evaluated. The majority of male patients (84) had urethral gonorrhoea, but four had rectal and two pharyngeal infections. Four patients had positive cultures at more than one site (two urethral and rectal; two urethral and pharyngeal). All nine female patients had infection of the cervix only. Bacteriological eradication of N. gonorrhoeae was achieved in 76/82 (93%) patients with positive urethral cultures, 9/9 with positive cervical, 4/4 with positive rectal, and 2/2 with positive pharyngeal cultures. Twenty-two patients (18 males, four females) had concomitant chlamydial infection. Chlamydia trachomatis was eradicated in all patients who returned for follow-up assessment and in whom culture was done. Azithromycin was very well tolerated, with only two patients reporting mild-to-moderate side-effects. This study shows that single-dose azithromycin is effective in uncomplicated gonorrhoea and in mixed gonococcal and chlamydial infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396093     DOI: 10.1093/jac/31.suppl_e.193

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations.

Authors:  L Zarantonelli; G Borthagaray; E H Lee; W M Shafer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.

Authors:  Ellen N Kersh; Vanessa Allen; Eric Ransom; Matthew Schmerer; Sancta Cyr; Kim Workowski; Hillard Weinstock; Jean Patel; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Antimicrobial resistance of Neisseria gonorrhoeae isolates from the Stuttgart and Heidelberg areas of southern Germany.

Authors:  M Enders; A Turnwald-Maschler; T Regnath
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-05       Impact factor: 3.267

Review 5.  Treatment of sexually transmitted bacterial diseases in pregnant women.

Authors:  G G Donders
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 6.  Concurrent gonococcal and chlamydial infection: how best to treat.

Authors:  A J Robinson; G L Ridgway
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

7.  Azithromycin and syphilis.

Authors:  F J Bowden; B Farmer; J Bullen; V Chamberlain; I Bastian
Journal:  Genitourin Med       Date:  1995-06

8.  Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis.

Authors:  Midori Soda; Shin Ito; Naoki Matsumaru; Sakiko Nakamura; Izumi Nagase; Hikari Takahashi; Yuta Ohno; Mitsuru Yasuda; Miho Yamamoto; Katsura Tsukamoto; Yoshinori Itoh; Takashi Deguchi; Kiyoyuki Kitaichi
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 9.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

10.  Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.

Authors:  P C Mehaffey; S D Putnam; M S Barrett; R N Jones
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.